Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on January 6 and set a price target of $181.00. The company’s shares closed ...

It’s called JnJ Bakery Cafe, and you’ll find it on Barrette Street where the much-loved taco place Ola Cocina Taqueria had been for quite a few years. In the weeks before the holidays ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage ...

Speaker of the House of Rep. Mike Johnson. Kevin Dietsch/Getty Images After it appeared there were too many Republican defections to win the vote, Rep. Mike Johnson retained his role as House ...

Johnson & Johnson (NYSE:JNJ) has announced that the U.S. FDA has declined to approve an injectable version of its cancer medication Rybrevant (amivantamab-vmjw) developed with Halozyme ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of ...